# ClinicalIntelPulse Mechanism-of-Action Map

> ClinicalIntelPulse Mechanism-of-Action Map is a paid API for AI agents from clinicalintelpulse.theaslangroupllc.com, paid per call via x402, $0.2/call, status unknown (last checked 2026-09-14).

Returns the drug mechanism-of-action and molecular target landscape for a disease, including targets in active trials, approved agents by MOA, crowded vs. novel mechanisms, first-in-class openings, and key publications.

## Facts

- Endpoint: GET https://clinicalintelpulse.theaslangroupllc.com/api/clinical/mechanism-map
- Price: $0.2/call
- Payment: x402
- Status: unknown
- Last checked: 2026-09-14
- Activations on Zero: 0
- Tags: x402
- Canonical page: https://www.zero.xyz/c/clinicalintelpulse-mechanism-of-action-map-f26b215f
- Structured record (JSON): https://api.zero.xyz/v1/capabilities/cap_HdqNsBR_Y3xVOij02EpEo

Status and success rate cover calls made through Zero and Zero's own probes. Third-party monitors may report differently.

## How to call it through Zero

Zero handles the 402 payment challenge and records the run. With the Zero CLI installed (`npm i -g @zeroxyz/cli`):

```sh
zero fetch --capability clinicalintelpulse-mechanism-of-action-map-f26b215f
```

Example prompt: Can you pull the full mechanism-of-action and molecular target landscape for non-alcoholic steatohepatitis — I want to see which targets are active in trials, what MOAs are already crowded with approved drugs, and where there are first-in-class openings?

## When to prefer this

Use this endpoint when you need a strategic MOA-level view of a disease space — specifically to understand which molecular targets are pursued in trials, which drug classes are saturated, and where first-in-class or best-in-class opportunities exist. Prefer this over a general pipeline endpoint when the primary question is about mechanism whitespace or target biology rather than company-level competitive intelligence or specific trial design details.

## Known failure modes

- Unknown or ambiguous disease name returns an empty or error response
- Very rare diseases with minimal trial activity may return sparse target data
- Highly novel targets not yet in registered trials will be absent from the map
- Rate limiting or payment failure (x402) if USDC balance is insufficient
- Stale data if underlying trial registries have not been recently synced

## How this service works

Drug mechanism-of-action + molecular target landscape for any disease — targets in active trials, approved agents by MOA, crowded vs novel mechanisms and first-in-class openings, with key publications. Worldwide. For drug-discovery and VC agents.

## Output

A structured landscape of molecular targets and drug mechanisms for the queried disease, including: which targets have drugs in active clinical trials, approved agents organized by MOA, identification of overcrowded vs. novel mechanisms, first-in-class whitespace opportunities, and links or citations to key supporting publications. Worldwide scope.

## Request schema (JSON Schema)

```json
{
 "type": "object",
 "$schema": "https://json-schema.org/draft/2020-12/schema",
 "required": [
  "input"
 ],
 "properties": {
  "input": {
   "type": "object",
   "required": [
    "type",
    "method"
   ],
   "properties": {
    "type": {
     "type": "string",
     "const": "http"
    },
    "method": {
     "enum": [
      "GET",
      "HEAD",
      "DELETE"
     ],
     "type": "string"
    },
    "queryParams": {
     "type": "object",
     "properties": {
      "lang": {
       "type": "string"
      },
      "condition": {
       "type": "string"
      },
      "mechanism": {
       "type": "string"
      }
     }
    }
   },
   "additionalProperties": false
  },
  "output": {
   "type": "object",
   "required": [
    "type"
   ],
   "properties": {
    "type": {
     "type": "string"
    },
    "errors": {
     "type": "object",
     "description": "Documented error responses, keyed by HTTP status code",
     "additionalProperties": {
      "type": "object",
      "required": [
       "description"
      ],
      "properties": {
       "example": {
        "type": "object"
       },
       "description": {
        "type": "string"
       }
      }
     }
    },
    "example": {
     "type": "object"
    }
   }
  }
 }
}
```

## Response schema (JSON Schema)

```json
{
 "type": "json",
 "example": {
  "query_summary": {
   "condition": "Multiple Sclerosis",
   "mechanism": null
  },
  "key_publications": [
   {
    "year": "2024",
    "title": "BTK inhibitors in progressive MS — mechanisms and clinical data",
    "journal": "Nature Reviews Neurology"
   }
  ],
  "mechanism_landscape": {
   "white_spaces": [
    "Progressive MS neuroprotection",
    "Remyelination",
    "CNS innate immunity",
    "Biomarker-stratified precision approaches"
   ],
   "crowded_spaces": [
    "Anti-CD20 (3 approved, 2 in pipeline)",
    "S1P modulators (4 approved)",
    "Natalizumab analogues"
   ],
   "approved_mechanisms": [
    {
     "moa": "Anti-CD20 (B cell depletion)",
     "drugs": [
      "Ocrelizumab",
      "Ofatumumab",
      "Ublituximab"
     ],
     "notes": "Dominant mechanism for RRMS — 3 approved"
    },
    {
     "moa": "S1P receptor modulator",
     "drugs": [
      "Fingolimod",
      "Siponimod",
      "Ozanimod",
      "Ponesimod"
     ],
     "notes": "Oral DMT — 4 approved; class mature"
    },
    {
     "moa": "BTK inhibitor",
     "drugs": [],
     "notes": "No approvals yet — 6 agents in Phase 2/3"
    }
   ],
   "pipeline_mechanisms": [
    {
     "moa": "BTK inhibition (CNS-penetrant)",
     "phase": "PHASE3",
     "agents": [
      "Fenebrutinib (Roche)",
      "Tolebrutinib (Sanofi)",
      "Evobrutinib (Merck)"
     ],
     "crowding": "Moderate (3 Phase 3)",
     "differentiation": "Targets microglial activation — may address progressive MS unlike existing agents"
    },
    {
     "moa": "Remyelination (opioid receptor modulation)",
     "phase": "PHASE2",
     "agents": [
      "Opicinumab (Biogen)"
     ],
     "crowding": "Low",
     "differentiation": "Novel — no approved remyelinating agents"
    }
   ]
  },
  "drug_discovery_implications": "BTK inhibition is the most clinically advanced novel mechanism. CNS penetration and microglial targeting differentiate from older agents. Progressive MS remains the largest unmet need.",
  "first_in_class_opportunities": [
   "BTK inhibitors for progression (if Phase 3 data positive)",
   "Remyelinating agents (no approved class)"
  ]
 }
}
```

## More

- Live health (JSON, refreshed every minute): https://www.zero.xyz/c/clinicalintelpulse-mechanism-of-action-map-f26b215f/health.json
- [Zero catalog index](https://www.zero.xyz/llms.txt)
- [Other services from clinicalintelpulse.theaslangroupllc.com](https://www.zero.xyz/host/clinicalintelpulse.theaslangroupllc.com/llms.txt)